Aspira Womens Health (FRA:CUL) FCF Margin % : -162.57% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aspira Womens Health's Free Cash Flow for the three months ended in Dec. 2023 was €-3.18 Mil. Aspira Womens Health's Revenue for the three months ended in Dec. 2023 was €1.95 Mil. Therefore, Aspira Womens Health's FCF Margin % for the quarter that ended in Dec. 2023 was -162.57%.

As of today, Aspira Womens Health's current FCF Yield % is -48.48%.

The historical rank and industry rank for Aspira Womens Health's FCF Margin % or its related term are showing as below:

FRA:CUL' s FCF Margin % Range Over the Past 10 Years
Min: -892.05 Med: -354.89 Max: -173.89
Current: -174.06

During the past 13 years, the highest FCF Margin % of Aspira Womens Health was -173.89%. The lowest was -892.05%. And the median was -354.89%.

FRA:CUL's FCF Margin % is ranked worse than
82.88% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.815 vs FRA:CUL: -174.06

Aspira Womens Health FCF Margin % Historical Data

The historical data trend for Aspira Womens Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health FCF Margin % Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-288.66

-327.33

-404.84

-382.44

-173.90

Aspira Womens Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-332.19	-246.69	-137.36	-149.83	-162.57

Competitive Comparison of Aspira Womens Health's FCF Margin %

For the Diagnostics & Research subindustry, Aspira Womens Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's FCF Margin % falls into.

Aspira Womens Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aspira Womens Health's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-14.597	/	8.394
	=	-173.90 %

Aspira Womens Health's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.175	/	1.953
	=	-162.57 %

Aspira Womens Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » FCF Margin %

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines